Drug Profile
Research programme: small-molecule compounds - CytoCure
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator CytoCure
- Class Antineoplastics; Small molecules
- Mechanism of Action Antigen stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Malignant-melanoma(Combination therapy) in USA
- 02 Aug 2016 Early research in Malignant melanoma (Combination therapy) in USA (unspecified route)